Case number 2022-2124
Takeda Pharmaceutical Company Limited v. Zydus Pharmaceuticals (USA) Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 20, 2023 | 53 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [964410] [MVH] [Entered: 11/20/2023 10:51 AM] (1) |
| Oct 11, 2023 | 52 | JUDGMENT. AFFIRMED. Issued pursuant to Federal Circuit Rule 36. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [955473] [MJL] [Entered: 10/11/2023 09:04 AM] (2) |
| Oct 4, 2023 | 51 | Submitted after ORAL ARGUMENT to Panel: Moore, Chief Judge; Stoll, Circuit Judge and Cunningham, Circuit Judge.Arguing counsel: Steven J. Moore for Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. and Eric J. Lobenfeld for Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A., Inc.Oral Argument Audio available here. [954486] [MJL] [Entered: 10/04/2023 04:24 PM] (0) |
| Sep 27, 2023 | 50 | Notice to Counsel: Court operations, including all hearings scheduled for the District of Columbia and Georgia sittings during the courtâ??s October court week, will proceed as scheduled without disruption. Arguing counsel are expected to appear in person as scheduled for argument regardless of any lapse in federal appropriations. [952711] [MJL] [Entered: 09/27/2023 09:55 AM] (0) |
| Sep 25, 2023 | 49 | Response to notice of oral argument from Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/25/2023 by email. [952256] [22-2124] [Eric Lobenfeld] [Entered: 09/25/2023 02:41 PM] (1) |
| Sep 20, 2023 | 48 | Response to notice of oral argument from Appellants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd.. Service: 09/20/2023 by email. [951347] [22-2124] [Steven Moore] [Entered: 09/20/2023 04:14 PM] (1) |
| Sep 15, 2023 | 47 | Clerk's letter to the parties regarding oral argument in Atlanta, GA. Service as of this date by the Clerk of Court. [950193] [MJL] [Entered: 09/15/2023 10:02 AM] (1) |
| Sep 12, 2023 | 46 | NOTICE OF ORAL ARGUMENT. Panel: 2310D. Case scheduled October 4, 2023. Response to Notice of Oral Argument due: 09/26/2023. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [949509] [MJL] [Entered: 09/12/2023 02:30 PM] (2) |
| Sep 12, 2023 | 45 | Amended Entry of Appearance for Eric J. Lobenfeld as counsel for Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/12/2023 by email. [949503] [22-2124] [Eric Lobenfeld] [Entered: 09/12/2023 02:23 PM] (1) |
| Aug 17, 2023 | 44 | Notice from Appellees Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceutical Company Limited regarding conflicts with oral argument. Service: 08/17/2023 by email. [944129] [22-2124] [Eric Lobenfeld] [Entered: 08/17/2023 08:13 PM] (2) |
| Aug 16, 2023 | 43 | Notice from Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. regarding conflicts with oral argument. Service: 08/16/2023 by email. [943590] [22-2124] [Steven Moore] [Entered: 08/16/2023 02:13 PM] (2) |
| Aug 15, 2023 | 42 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [943126] [CAB] [Entered: 08/15/2023 11:57 AM] (1) |
| Feb 8, 2023 | 41 | 6 paper copies of Doc. No. [35], [32], [25] received from Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. [903644] [VDW] [Entered: 02/13/2023 08:24 AM] (0) |
| Feb 7, 2023 | 39 | Notice from Appellees Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A., Inc. regarding conflicts with oral argument. None. Service: 02/07/2023 by email. [902644] [22-2124] [Eric Lobenfeld] [Entered: 02/07/2023 03:55 PM] (1) |
| Feb 7, 2023 | 38 | Notice from Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. regarding conflicts with oral argument. None. Service: 02/07/2023 by email. [902533] [22-2124] [Steven Moore] [Entered: 02/07/2023 01:39 PM] (1) |
| Feb 3, 2023 | 40 | 6 paper copies of Doc. No. [29] received from Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.. [902655] [VDW] [Entered: 02/07/2023 04:08 PM] (0) |
| Feb 1, 2023 | 37 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [901283] [EKD] [Entered: 02/01/2023 01:57 PM] (1) |
| Feb 1, 2023 | 36 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [901282] [EKD] [Entered: 02/01/2023 01:56 PM] (0) |
| Feb 1, 2023 | 35 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. Service: 02/01/2023 by email. [901223] --[Edited 02/01/2023 by EKD - compliance review complete] [Steven Moore] [Entered: 02/01/2023 12:05 PM] (1433) |
| Jan 30, 2023 | 34 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc., Appendix [33], is not in compliance with the rules of this court (see attached). Compliant document due on 02/06/2023. Service as of this date by the Clerk of Court. [900533] [EKD] [Entered: 01/30/2023 12:57 PM] (1) |
| Jan 27, 2023 | 33 | APPENDIX FILED by Service: 01/27/2023 by email. [900403] [22-2124] This document is non-compliant. See Doc No. [34] [James Nealon] [Entered: 01/27/2023 11:11 PM] (1433) |
| Jan 27, 2023 | 32 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. Service: 01/27/2023 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [900401] --[Edited 01/30/2023 by EKD - compliance review complete] [James Nealon] [Entered: 01/27/2023 11:06 PM] (34) |
| Jan 3, 2023 | 31 | **TEXT ONLY** ORDER granting motion to extend time to file brief [30] filed by Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. The reply brief is due 01/27/2023. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [894268] [EKD] [Entered: 01/03/2023 04:04 PM] (0) |
| Jan 2, 2023 | 30 | MOTION of Appellants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. to extend the time to 01/27/2023 to file brief. Service: 01/02/2022 by email. [894033] [22-2124] [James Nealon] [Entered: 01/02/2023 05:02 PM] (8) |
| Dec 27, 2022 | 29 | MODIFIED ENTRY: RESPONSE BRIEF FILED by Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., and Takeda Pharmaceuticals U.S.A., Inc. Service: 12/27/2022 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [892989] --[Edited 12/27/2022 by EKD - compliance review complete] [Eric Lobenfeld] [Entered: 12/27/2022 11:06 AM] (26) |
| Dec 5, 2022 | 27 | **TEXT ONLY** ORDER granting motion to extend time to file brief [26] filed by Appellees Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Limited, and Takeda Pharmaceuticals U.S.A., Inc. The response brief is due 12/27/2022. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [888225] [EKD] [Entered: 12/05/2022 11:59 AM] (0) |
| Dec 5, 2022 | 28 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Doc No. [26], ERROR: (1) The Certificate of Interest is incomplete. (2) The document contains non-compliant signatures. CORRECTION: For future filings, please (1) include a complete Certificate of Interest, and (2) use an electronic signature consisting of the printed name of the individual preceded by the mark /s/ entered on the signature line. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [888227] [EKD] [Entered: 12/05/2022 12:01 PM] (0) |
| Dec 2, 2022 | 26 | MOTION of Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc. to extend the time to 12/27/2022 to file brief. Service: 12/02/2022 by email. [887753] [22-2124] [Eric Lobenfeld] [Entered: 12/02/2022 10:07 AM] (6) |
| Nov 20, 2022 | 25 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. Service: 11/20/2022 by email. [885233] --[Edited 11/22/2022 by EKD - compliance review complete] [James Nealon] [Entered: 11/20/2022 05:10 PM] (96) |
| Nov 14, 2022 | 24 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc., Corrected Opening Brief [23], is not in compliance with the rules of this court (see attached). Compliant document due on 11/21/2022. Service as of this date by the Clerk of Court. [883668] [EKD] [Entered: 11/14/2022 10:20 AM] (1) |
| Nov 9, 2022 | 23 | CORRECTED OPENING BRIEF FILED by Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 11/09/2022 by email. [883260] [22-2124] This document is non-compliant. See Doc No. [24] [James Nealon] [Entered: 11/09/2022 04:20 PM] (96) |
| Nov 3, 2022 | 22 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc., Opening Brief [21], is not in compliance with the rules of this court (see attached). Compliant document due on 11/10/2022. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [881952] [EKD] [Entered: 11/03/2022 10:15 AM] (2) |
| Oct 31, 2022 | 21 | OPENING BRIEF FILED by Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. Service: 10/31/2022 by email. [881372] [22-2124] This document is non-compliant. See Doc No. [22] [James Nealon] [Entered: 10/31/2022 10:28 PM] (96) |
| Oct 12, 2022 | 20 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Doc No. [18], ERROR: The motion does not include a Certificate of Interest or certificate of compliance with the word count. CORRECTION: For future filings, please include a Certificate of Interest and a certificate of compliance stating the exact word count. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [877206] [EKD] [Entered: 10/12/2022 11:23 AM] (0) |
| Oct 12, 2022 | 19 | **TEXT ONLY** ORDER granting motion to extend time to file brief [18] filed by Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. The opening brief is due 10/31/2022. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [877205] [EKD] [Entered: 10/12/2022 11:22 AM] (0) |
| Oct 10, 2022 | 18 | MOTION of Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. to extend the time to 10/31/2022 to file brief. Service: 10/10/2022 by email. [876818] [22-2124] [James Nealon] [Entered: 10/10/2022 01:12 PM] (4) |
| Oct 4, 2022 | 17 | Corrected Entry of Appearance for Steven J. Moore; James E. Nealon as counsel for Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 10/04/2022 by email. [875662] [22-2124] [Steven Moore] [Entered: 10/04/2022 11:13 AM] (1) |
| Sep 30, 2022 | 16 | Entry of Appearance for Ryan J. Stephenson as counsel for Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/30/2022 by email. [875032] [22-2124] [Ryan Stephenson] [Entered: 09/30/2022 11:46 AM] (1) |
| Sep 29, 2022 | 15 | Notice to Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.: The record of this case indicates that no compliant Entry of Appearance under FCR 47.3(b) has been filed. Failure to file required documents may result in dismissal or other action as deemed appropriate by the court. See FCR 25(h). Service as of this date by the Clerk of Court. [874793] [EKD] [Entered: 09/29/2022 02:31 PM] (0) |
| Sep 16, 2022 | 14 | Docketing Statement for the Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/16/2022 by email. [872131] [22-2124] [Eric Lobenfeld] [Entered: 09/16/2022 08:17 AM] (2) |
| Sep 15, 2022 | 13 | Notice to Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.: The record of this case indicates that no Docketing Statement under FCR 33.1(a) has been filed. Failure to file required documents may result in dismissal or other action as deemed appropriate by the court. See FCR 25(h). Service as of this date by the Clerk of Court. [871951] [EKD] [Entered: 09/15/2022 11:06 AM] (0) |
| Sep 12, 2022 | 12 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc., Corrected Entry of Appearance [11], is not in compliance with the rules of this court (see attached). Compliant document due on 09/19/2022. Service as of this date by the Clerk of Court. [871128] [EKD] [Entered: 09/12/2022 11:37 AM] (1) |
| Sep 5, 2022 | 11 | Corrected Entry of appearance for Steven J. Moore; James E. Nealon as counsel for Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 09/05/2022 by email. [869867] [22-2124] [Steven Moore] [Entered: 09/05/2022 04:25 PM] (1) |
| Sep 5, 2022 | 10 | Corrected Certificate of Interest for Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 09/05/2022 by email. [869866] [22-2124] [Steven Moore] [Entered: 09/05/2022 04:20 PM] (3) |
| Sep 1, 2022 | 9 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Doc No. [8], ERROR: The Filing Party/Entity line does not list all represented parties. CORRECTION: For future filings, please include all parties the document is filed on behalf of when asked for the filing party/entity. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [869526] [EKD] [Entered: 09/01/2022 02:34 PM] (0) |
| Aug 30, 2022 | 8 | Certificate of Interest for Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.. Service: 08/30/2022 by clerk. [868974] [22-2124] [Eric Lobenfeld] [Entered: 08/30/2022 03:06 PM] (4) |
| Aug 30, 2022 | 7 | Entry of appearance for Eric J. Lobenfeld; Benjamin F. Holt as counsel for Appellees Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc.. Service: 08/30/2022 by clerk. [868971] [22-2124] [Eric Lobenfeld] [Entered: 08/30/2022 03:04 PM] (1) |
| Aug 29, 2022 | 6 | NOTICE OF NON-COMPLIANCE: The submissions of Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc., Certificate of Interest and Entry of Appearance [4], [5], are not in compliance with the rules of this court (see attached). Compliant documents are due on 09/06/2022. Service as of this date by the Clerk of Court. [868633] [EKD] [Entered: 08/29/2022 12:13 PM] (2) |
| Aug 26, 2022 | 5 | Corrected Entry of appearance for Steven J. Moore as counsel for Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 08/26/2022 by email. [868475] [22-2124] This document is non-compliant. See Doc No. [6] [Steven Moore] [Entered: 08/26/2022 02:43 PM] (1) |
| Aug 26, 2022 | 4 | Certificate of Interest for Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 08/26/2022 by email. [868463] [22-2124] This document is non-compliant. See Doc No. [6] [Steven Moore] [Entered: 08/26/2022 02:06 PM] (3) |
| Aug 26, 2022 | 3 | Docketing Statement for the Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 08/26/2022 by email. [868462] [22-2124] [Steven Moore] [Entered: 08/26/2022 02:05 PM] (2) |
| Aug 26, 2022 | 2 | Entry of appearance for Steven J. Moore as counsel for Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 08/16/2022 by clerk. [868459] [22-2124] [Steven Moore] [Entered: 08/26/2022 02:02 PM] (1) |
| Aug 16, 2022 | 1 | Appeal docketed. Received: 08/10/2022. [866804]Entry of Appearance is due 08/30/2022. Certificate of Interest is due on 08/30/2022. Docketing Statement is due on 08/30/2022. Appellant's brief is due on 10/17/2022. [EKD] [Entered: 08/16/2022 01:18 PM] (37) |
